세계의 식도암 시장 보고서(2025년)
Esophageal Cancer Global Market Report 2025
상품코드 : 1824376
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

식도암 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 21억 6,000만 달러로 성장하며 CAGR은 9.3%가 됩니다. 예측 기간의 성장은 식도암의 유병률 상승, 헬스케어에 대한 일반 시민의 이해 증가, 헬스케어 인프라의 개선, 흡연과 알코올의 만성적인 소비, 식도선암의 유병률 증가 등에 기인한다고 생각됩니다. 예측 기간의 주요 동향으로는 치료선택의 기술적 진보, 연구개발투자 증가, 정밀의료 활용 증가, 표적치료의 개발, 임상시험 참여 증가, 학계·제약기업·헬스케어기관의 제휴 등을 들 수 있습니다.

향후 5년간의 성장률 9.3%라고 하는 예측은 전회의 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과는 일본과 네덜란드에서 수입되는 체크포인트 억제제나 식도 스텐트에 대한 접근을 제한하고, 암 치료의 결과를 해치고, 암 치료의 부담을 증가시킬 가능성이 있기 때문에 미국에 있어서 큰 과제가 될 가능성이 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

식도암의 이환율 상승은 식도암 시장 성장을 가속할 것으로 예측됩니다. 식도암은 목과 위를 연결하는 관인 식도를 침범하는 악성 종양입니다. 더 많은 사례가 진단됨에 따라 질병을 발견하고 확인하기 위한 내시경 검사, 영상 검사, 생검 등 진단 절차에 대한 수요가 증가합니다. 예를 들어 미국을 거점으로 하는 전문기관인 미국암협회에 따르면 2023년에는 식도암에 의한 새로운 사망자 수는 1만 6,120명이었으며, 2024년에는 1만 6,130명으로 증가했습니다. 따라서 식도암 증례 증가가 식도암 시장 성장을 가속할 것으로 예측됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Esophageal cancer is a form of cancer originating in the cells that line the esophagus, the muscular tube responsible for transporting food and liquids from the neck to the stomach. This malignancy occurs when abnormal cells within the esophagus undergo uncontrolled growth, leading to the development of cancer.

The primary classifications of esophageal cancer include esophageal squamous-cell carcinoma, esophageal adenocarcinoma, and other subtypes. Esophageal squamous-cell carcinoma specifically emerges from the squamous cells lining the esophagus. Treatment options encompass chemotherapy, targeted therapy, and various other approaches, which can be administered orally, parenterally, and through alternative methods. The distribution of treatment products occurs through channels such as hospital pharmacies, online pharmacies, and retail pharmacies, serving institutions such as hospitals, homecare services, specialty centers, and other healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The esophageal cancer research report is one of a series of new reports from The Business Research Company that provides esophageal cancer market statistics, including the esophageal cancer industry's global market size, regional shares, competitors with a esophageal cancer market share, detailed esophageal cancer market segments, market trends and opportunities, and any further data you may need to thrive in the esophageal cancer industry. This esophageal cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry

The esophageal cancer market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.51 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to increased number of cancers, improvement in healthcare infrastructure, rise in alcohol consumption, growth in demand for preventive healthcare solutions, increase in prevalence of esophageal adenocarcinoma.

The esophageal cancer market size is expected to see strong growth in the next few years. It will grow to $2.16 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to rising prevalence of esophageal cancer, increasing public understanding of healthcare, improvements in healthcare infrastructure, chronic consumption of smoking and alcohol, increasing prevalence of esophageal adenocarcinoma. Major trends in the forecast period include technological advancements in treatment options, increased investment in research and development, increasing utilization of precision medicine, development of targeted therapies, increased participation in clinical trials and collaborations between academia, pharmaceutical companies, and healthcare institutions.

The forecast of 9.3% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to checkpoint inhibitors and esophageal stents imported from Japan and the Netherlands, potentially compromising cancer treatment outcomes and increasing oncology care burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of esophageal cancer is expected to drive growth in the esophageal cancer market. Esophageal cancer is a malignancy that affects the esophagus, the tube connecting the throat to the stomach. As more cases are diagnosed, there will be an increased demand for diagnostic procedures such as endoscopy, imaging tests, and biopsies to detect and confirm the disease. For example, the American Cancer Society, a US-based professional organization, reported that in 2023, there were 16,120 new deaths from esophageal cancer, with projections indicating this number will rise to 16,130 in 2024. Therefore, the increase in esophageal cancer cases is anticipated to propel the growth of the esophageal cancer market.

Increased consumption of alcohol is also anticipated to fuel the growth of the esophageal cancer market. Alcohol consumption involves ingesting beverages containing ethanol, which metabolizes into acetaldehyde, a known carcinogen that can damage DNA in esophageal cells. Chronic alcohol consumption can lead to inflammation and irritation in the esophageal lining, creating a conducive environment for cancer development. Notably, in November 2023, data from the Substance Abuse and Mental Health Services Administration (SAMHSA) revealed a rise in alcohol consumption among the 133.1 million current alcohol users aged 12 or older in the United States in 2021. Of these, 25.8 percent reported binge drinking in the past month, and 6.3 percent reported heavy alcohol use during the same period. Moreover, 14.4 million individuals aged 12 or older experienced an alcohol use disorder in the past year, constituting 5.3 percent of people in this age group. Consequently, high alcohol consumption is expected to contribute to the growth of the esophageal cancer market.

The approval of new drugs stands out as a significant trend gaining traction in the esophageal cancer market. Major companies within the esophageal cancer market are directing their efforts towards securing approvals for new drugs, a strategy aimed at enhancing their market position and gaining a competitive edge. An illustrative example is Bristol Myers Squibb, a US-based pharmaceutical company, which obtained approval from the U.S. Food and Drug Administration (FDA) in May 2022 for two of its products such as Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab). These products, primarily designed for individuals with advanced or metastatic esophageal squamous cell carcinoma (ESCC), received authorization based on favorable outcomes observed in Phase 3 clinical trials, demonstrating improved overall survival rates among treated patients.

A focus on precision medicine is also evident among major companies operating in the esophageal cancer market, as reflected in product launches. Precision medicine represents an innovative approach to medical treatment that tailors interventions based on individual patients' unique genetic, environmental, and lifestyle characteristics. Previse, a US-based biotechnology company, launched Esopredict in March 2023-a precision medicine solution empowering gastroenterologists to tailor approaches effectively for managing the risk of future cancer diagnoses. Esopredict utilizes The Esoscore derived from Barrett's esophagus cells to offer timely and accurate 5-year risk predictions for esophageal cancer. This groundbreaking product addresses an essential medical need by aiding healthcare providers in identifying patients at risk of progressing to high-grade dysplasia or esophageal cancer, thereby revolutionizing treatment approaches and significantly impacting the esophageal cancer market.

In January 2023, ProPhase Labs, Inc., a US-based next-generation biotech, genomics, and diagnostics company, acquired the rights to the BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test from Stella Diagnostics, Inc. This strategic move positions ProPhase Labs to facilitate healthcare providers in promptly initiating life-saving early treatment measures, such as ablation procedures to eliminate precancerous cells. Stella Diagnostics, Inc., a US-based molecular diagnostics organization, focuses on enhancing patient management strategies.

Major companies operating in the esophageal cancer market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Servier Pharmaceuticals, Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Ipsen SA, Dr. Reddy's Laboratories Ltd., Seagen Inc., Exelixis Inc., BeiGene Ltd., Clovis Oncology Inc., Aslan Pharmaceuticals Ltd.

North America was the largest region in the esophageal cancer market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the esophageal cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the esophageal cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The esophageal cancer market consists of revenues earned by entities by providing esophageal cancer treatment services such as esophagectomy, palliative care, and brachytherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The esophageal cancer market consists of sales of fluorouracil, capecitabine, cisplatin, epirubicin, and docetaxel. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Esophageal Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on esophageal cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for esophageal cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The esophageal cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Esophageal Cancer Market Characteristics

3. Esophageal Cancer Market Trends And Strategies

4. Esophageal Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Esophageal Cancer Growth Analysis And Strategic Analysis Framework

6. Esophageal Cancer Market Segmentation

7. Esophageal Cancer Market Regional And Country Analysis

8. Asia-Pacific Esophageal Cancer Market

9. China Esophageal Cancer Market

10. India Esophageal Cancer Market

11. Japan Esophageal Cancer Market

12. Australia Esophageal Cancer Market

13. Indonesia Esophageal Cancer Market

14. South Korea Esophageal Cancer Market

15. Western Europe Esophageal Cancer Market

16. UK Esophageal Cancer Market

17. Germany Esophageal Cancer Market

18. France Esophageal Cancer Market

19. Italy Esophageal Cancer Market

20. Spain Esophageal Cancer Market

21. Eastern Europe Esophageal Cancer Market

22. Russia Esophageal Cancer Market

23. North America Esophageal Cancer Market

24. USA Esophageal Cancer Market

25. Canada Esophageal Cancer Market

26. South America Esophageal Cancer Market

27. Brazil Esophageal Cancer Market

28. Middle East Esophageal Cancer Market

29. Africa Esophageal Cancer Market

30. Esophageal Cancer Market Competitive Landscape And Company Profiles

31. Esophageal Cancer Market Other Major And Innovative Companies

32. Global Esophageal Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Esophageal Cancer Market

34. Recent Developments In The Esophageal Cancer Market

35. Esophageal Cancer Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기